Patient with Systemic Lupus Erythematosus who Presented with Area Postrema Syndrome after COVID-19 Vaccination

Carlos Romero-Gómez^1, , Pablo López-Quirantes¹, José Antonio Reyes-Bueno² and Ricardo Gómez-Huelgas¹

¹Medicina Interna, Hospital Regional Universitario, Málaga, Spain

²Neurología, Hospital Regional Universitario, Málaga, Spain

Cite this paper:
Carlos Romero-Gómez, Pablo López-Quirantes, José Antonio Reyes-Bueno and Ricardo Gómez-Huelgas. Patient with Systemic Lupus Erythematosus who Presented with Area Postrema Syndrome after COVID-19 Vaccination. American Journal of Medical Case Reports. 2022; 10(3):72-76. doi: 10.12691/ajmcr-10-3-8

Abstract

Area postrema syndrome is a disorder that is included within the neuromyelitis optica spectrum (NMOSD), a group of severe inflammatory disorders of the central nervous system that primarily affect the optic nerve and spinal cord. The cause of NMOSD is unknown, but it has been linked to infections, vaccines and associated with autoimmune diseases. We present the case of a patient with a history of systemic lupus erythematosus who presented with area postrema syndrome after vaccination with COVID-19.

Keywords:
postrema area syndrome neuromyelitis optica systemic lupus erythematosus covid-19 vaccination

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]	Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6(9): 805-815.
[2]	Patterson SL, Goglin SE. Neuromyelitis Optica. Rheum Dis Clin North Am. 2017; 43(4): 579-591.
[3]	Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015; 85(2): 177-189.
[4]	Camara-Lemarroy CR, Burton JM. Area postrema syndrome: A short history of a pearl in demyelinating diseases. Mult Scler. 2019; 25(3): 325-329.
[5]	Flanagan EP. Neuromyelitis Optica Spectrum Disorder and Other Non-Multiple Sclerosis Central Nervous System Inflammatory Diseases. Contin (Minneap Minn). 2019; 25(3): 815-844.
[6]	Chan KH, Lee CY. Treatment of neuromyelitis optica spectrum disorders. Int J Mol Sci. 2021; 22(16): 1-27.
[7]	Kumar N, Graven K, Joseph NI, et al. Case Report: Postvaccination Anti-Myelin Oligodendrocyte Glycoprotein Neuromyelitis Optica Spectrum Disorder: A Case Report and Literature Review of Postvaccination Demyelination. Int J MS Care. 2020; 22(2): 85-90.
[8]	Hu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. 2021; 19(3): 141-154.
[9]	Finsterer J. Neurological side effects of SARS-CoV-2 vaccinations. Acta Neurol Scand. 2022; 145(1): 5-9.
[10]	Khayat-Khoei M, Bhattacharyya S, Katz J, et al. COVID-19 mRNA vaccination leading to CNS inflammation: a case series. J Neurol. 2021; (0123456789).
[11]	Karussis D, Petrou P. The spectrum of post-vaccination inflammatory CNS demyelinating syndromes. Autoimmun Rev. 2014; 13(3): 215-224.
[12]	Badrawi N, Kumar N, Albastaki U. Post COVID-19 vaccination neuromyelitis optica spectrum disorder: Case report & MRI findings. Radiol case reports. 2021; 16(12): 3864-3867.
[13]	Chen S, Fan XR, He S, Zhang JW, Li SJ. Watch out for neuromyelitis optica spectrum disorder after inactivated virus vaccination for COVID-19. Neurol Sci. 2021; 42(9): 3537-3539.
[14]	Fujikawa P, Shah FA, Braford M, Patel K, Madey J. Neuromyelitis Optica in a Healthy Female After Severe Acute Respiratory Syndrome Coronavirus 2 mRNA-1273 Vaccine. Cureus. 2021; 13(9):e17961.
[15]	Pagenkopf C, Südmeyer M. A case of longitudinally extensive transverse myelitis following vaccination against Covid-19. J Neuroimmunol. 2021; 358(January): 577606.
[16]	Songthammawat T, Srisupa-Olan T, Siritho S, et al. A pilot study comparing treatments for severe attacks of neuromyelitis optica spectrum disorders: Intravenous methylprednisolone (IVMP) with add-on plasma exchange (PLEX) versus simultaneous ivmp and PLEX. Mult Scler Relat Disord. 2020; 38: 101506.
[17]	Cree BAC, Bennett JL, Kim HJ, et al. Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial. Lancet (London, England). 2019; 394 (10206): 1352-1363.
[18]	Araki M. Efficacy of the anti – IL-6 receptor antibody tocilizumab in neuromyelitis optica. Neurology. 2014; 82(15): 1302-1306.
[19]	Yamamura T, Kleiter I, Fujihara K, et al. Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(22): 2114-2124.
[20]	Pittock SJ, Berthele A, Fujihara K, et al. Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. N Engl J Med. 2019; 381(7): 614-625.